Cancer clinical trials in the region Île-de-France

726 currently recruiting clinical trials
Region Île-de-France

Phase 3 Lung cancer #NCT05918302 #2022-502154-13-00
Required histologic types
Neuroendocrine tumor/carcinoma other than SCLC
Required histologic sub types
Neuroendocrine tumor/carcinoid
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1 2
8 recruiting sites
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Pancreas cancer Stomach and esophageal cancer #NCT05477576 #2023-509334-19-00
Required histologic types
Stomach
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Somatostatin analogs
Required SSTR metabolic imaging statuses
SSTR Positive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
RayzeBio, Inc
Phase 3 Head and neck cancer #NCT06706401 #2022-501315-13-00
Required histologic types
Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery Immunotherapy Targeted therapy Radiotherapy Radiochemotherapy
8 recruiting sites
Centre Léon Bérard
Phase 3 Breast cancer #NCT05633654
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
Required previous treatments at advanced or metastatic stage
Surgery Chemotherapy Radiotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
15 recruiting sites
Gilead Sciences
Phase 3 Lung cancer #NCT06801834 #2024-515884-69-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Gilead Sciences
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT03534713
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required FIGO stages
Stage I Stage II Stage III Stage IV
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
11 recruiting sites
Hôpital universitaire de Toulouse
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05581121
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required FIGO stages
Stage III
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Radiotherapy
24 recruiting sites
Institut Claudius Regaud
Phase 3 Head and neck cancer #NCT04892173
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Surgery Chemotherapy Radiotherapy Radiochemotherapy
15 recruiting sites
Johnson & Johnson Enterprise Innovation Inc.
Phase 3 Acute leukemia #NCT07007312 #2025-521314-25-00
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
KMT2A NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
16 recruiting sites
Kura Oncologie, Inc.
Phase 3 Head and neck cancer #NCT07264075 #2025-522996-27-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
6 recruiting sites
Groupe Oncologie Radiothérapie Tête et Cou (GORTEC)